Table 3.

Comparison of eIF3m expression between different subtypes of breast cancer and breast

Author	Subtypes (sample)	P-value	Fold change
Curtis	IBC vs. Breast (21 vs. 144)	4.30E − 6	1.801
	BPT vs. Breast (5 vs. 144)	0.008	1.828
	TBC vs. Breast (67 vs. 144)	7.17E − 14	1.922
	IDLBC vs. Breast (90 vs. 144)	2.87E − 12	1.844
	IDBC vs. Breast (1556 vs. 144)	7.49E − 16	1.442
	BC vs. Breast (14 vs. 144)	0.024	1.284
	MBC1 vs. Breast (46 vs. 144)	6.08E − 8	1.635
	DBCS vs. Breast (10 vs. 144)	0.005	1.412
	MBC2 vs. Breast (32 vs. 144)	3.24E − 4	1.593
	ILBC vs. Breast (148 vs. 144)	4.64E − 7	1.338
	BBN vs. Breast (3 vs. 144)	0.057	1.437
Sorlie	DBC vs. Breast (92 vs. 4)	0.037	1.169
Ma	IDBC vs. Breast (9 vs. 14)	0.016	1.102
Richardson	DBC vs. Breast (40 vs. 7)	0.002	1.182
TCGA	IDBC vs. Breast (639 vs. 111)	9.24E − 5	1.030

IBC invasive breast carcinoma, BPT breast phyllodes tumor, TBC tubular breast carcinoma, IDLBC mixed invasive ductal and lobular breast carcinoma, IDBC invasive ductal breast carcinoma, BC breast carcinoma, MBC1 mucinous breast carcinoma, DBCS ductal breast carcinoma in situ; MBC2 medullary breast carcinoma, ILBC invasive lobular breast carcinoma, BBN benign breast neoplasm, DBC ductal breast carcinoma